September 30, 2022
Securities and Exchange Commission v. Vivera Pharmaceuticals, Inc. et al
Case Number:
8:22-cv-01792
Court:
Nature of Suit:
Judge:
Firms
Government Agencies
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
November 25, 2025
Judge Hands SEC Win In Pharma Co.'s CBD Investor Fraud Case
A California federal judge has granted the U.S. Securities and Exchange Commission an early win in its suit against Vivera Pharmaceuticals, its CEO and affiliate Sentar Pharmaceuticals, finding they misled investors about the company's rights to key cannabinoid drug-delivery technology and about how investor money would be spent.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what鈥檚 happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login